These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 16052895)
1. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation. Struve CT Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895 [No Abstract] [Full Text] [Related]
2. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval. O'Reilly JT Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397 [No Abstract] [Full Text] [Related]
3. Litigation plays protective role--and is part of the problem. Kennett JD Mo Med; 2007; 104(1):12-3. PubMed ID: 17410818 [No Abstract] [Full Text] [Related]
4. Recent legal developments and the authority of the Australian Therapeutic Goods Administration. Shirlow E; Faunce T J Law Med; 2009 May; 16(5):764-9. PubMed ID: 19554858 [TBL] [Abstract][Full Text] [Related]
5. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases. Shea LL; Hanson A; Guglielmetti TM; Levy K Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388 [No Abstract] [Full Text] [Related]
6. Contingent fees in mass tort litigation. Task Force on Contingent Fees of the American Bar Association's Tort Trial & Insurance Practice Section Tort Trial Insur Pract Law J; 2006; 42(1):105-31. PubMed ID: 17486724 [No Abstract] [Full Text] [Related]
7. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say. DerGurahian J Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373 [No Abstract] [Full Text] [Related]
8. Revisiting Factor VIII cases: is it time for an agency adjudication system? Su YC Food Drug Law J; 2008; 63(4):943-61. PubMed ID: 19601390 [No Abstract] [Full Text] [Related]
9. Use of vaginal mesh in the face of the recent FDA warnings and litigation. Steinberg AC Am J Obstet Gynecol; 2011 Jun; 204(6):e10; author reply e10-1. PubMed ID: 21292232 [No Abstract] [Full Text] [Related]
12. The FDA moves to implement the Safe Medical Devices Act. Tamborlane T Healthspan; 1992 Nov; 9(10):7-10. PubMed ID: 10122957 [No Abstract] [Full Text] [Related]
13. Civil and criminal liability associated with food recalls. Packman JM Food Drug Law J; 1998; 53(3):437-52. PubMed ID: 10346721 [No Abstract] [Full Text] [Related]
14. Greater and lesser powers of tort reform: the primary jurisdiction doctrine and state-law claims concerning FDA-approved products. Struve CT Cornell Law Rev; 2008 Jul; 93(5):1039-74. PubMed ID: 18618970 [No Abstract] [Full Text] [Related]
15. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions. Chodock R; Yolkut D; Connolly DR Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814 [TBL] [Abstract][Full Text] [Related]
16. New law gives FDA more influence to monitor drug safety. Wadman M Nat Med; 2007 Nov; 13(11):1269. PubMed ID: 17987008 [No Abstract] [Full Text] [Related]
17. US Senate passes FDA Revitalization Act. Guthrie P CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930 [No Abstract] [Full Text] [Related]
18. Companies to pay $39.5m in OxyContin and Risperdal cases. McCarthy M BMJ; 2015 Dec; 351():h7018. PubMed ID: 26721284 [No Abstract] [Full Text] [Related]
19. Immunity for immunizations: tort liability, biodefense, and Bioshield II. Mayer L Stanford Law Rev; 2007 Apr; 59(6):1753-90. PubMed ID: 17593591 [No Abstract] [Full Text] [Related]